SUPPLEMENTARY

Synthetic protocol used for synthesis

Procedure for the synthesis of quinazolin-4(3*H*)-ones (2a-c): Formamidine acetate (2 mmol) was added to a solution mixture of corresponding anthranilamide (1 mmol) in ethanol (30 mL) and refluxed for 6 h. After the reaction has completed, solvent was evaporated through vacuum evaporator. The residue was diluted with ethyl acetate (30 mL) and water (50 mL). The organic layer was collected and dried over anhydrous sodium sulfate followed by evaporation. The residue was purification by silica gel column chromatography using hexane: ethyl acetate (7:3) to give the corresponding quinazolin-4(3*H*)-one (2a-c) in good yield.

Procedure for the synthesis of 2-methyl-4*H*-benzo[*d*][1,3]oxazin-4-ones (4a-b): Acetic anhydride (15 mL) and corresponding anthranilic acid (1 mmol) solution were refluxed for an hour, followed by ice quenching and evaporation. The residue was washed with ethyl acetate (20 mL) and water (50 mL), and this step was repeated for three times. Organic layers were collected, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude residue was purified by silica gel column chromatography using hexane: ethyl acetate (6:4) as eluent to give the corresponding 2-methyl-4*H*-benzo[*d*][1,3]oxazin-4-one (4a-b).

Procedure for the synthesis of 2-methylquinazolin-4(3*H*)-ones (5a-b): The mixture of corresponding 2-methyl-4*H*-benzo[*d*][1,3]oxazin-4-one (4a-b) (1 mmol) in formamide (15 mL) solution was heated for 7 h at 130°C. Upon cooling, the solid residue was further washed with water and recrystallized the product using ethanol to give 2-methylquinazolin-4 (3*H*)-one (5a-b).

Procedure for the synthesis of 2-chloro-*N*-(aryl)acetamides (6a-f): To the solution mixture of different amines (1 mmol) and triethylamine (TEA) (3 mmol) in dimethylformamide (DMF) (15 mL), chloroacetyl chloride (2 mmol) was added drop wise at 0°C. The reaction was carried at for 3 h. Upon completion of the reaction, the solvent was evaporated, the residue was further extracted with water (20 mL) and ethyl acetate (30 mL), and the organic layer was washed with brine solution (20 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography using hexane: ethyl acetate (7:3) as eluent to give corresponding 2-chloro-*N*-(aryl) acetamides (6a-f).

Procedure for the synthesis of substituted 2-(4-oxoquinazolin-3(4*H*)-yl)acetamides (7-34): Anhydrous cesium carbonate (2 mmol) and respective quinazolin-4(3*H*)-one (2a-c/5a-b) (1 mmol) were added to the solution of corresponding 2-chloro-*N*-(aryl/heteroaryl) acetamides (6a-f) (1.2 mmol) in DMF (3 mL). The reaction was carried at 60°C for 3 h to complete. The residue was further diluted with water (10 mL) and ethyl acetate (20 mL) and the layers separated. The above extraction step was repeated thrice; the combined organic layers were washed with brine solution (15 mL), dried over anhydrous sodium sulfate, filtered, and evaporated. The residue was purified by silica column chromatography using hexane: ethyl acetate (8:2) to give substituted 2-(4-oxoquinazolin-3(4*H*)-yl) acetamides (7-34).

Characterization of synthesized compounds

Both analytical and spectral data (^{1}H NMR, ^{13}C NMR, and mass spectra) of all the synthesized compounds were in full agreement with the proposed structures.

Quinazolin-4(3*H*)-one (2a): The compound was synthesized according to the above general procedure using anthranilamide (2.0 g, 14.68 mmol) and formamidine acetate (3.05 g, 29.37 mmol) to afford 2a (1.95 g, 90.7%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.48 (s, 1H), 8.64 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.03–8.00 (t, J = 12Hz, 1H), 7.82–7.80 (d, J = 8Hz, 1H), 7.61–7.58 (t, J = 12Hz, 1H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 163.2, 152.3, 147.9, 136.1, 130.7, 127.3, 118.9. MS (ESI) *m/z* 147 $[M+H]^+$. Anal calcd for $C_8H_6N_2O$: C, 65.75; H, 4.14; N, 19.17 Found C, 65.68; H, 4.13; N, 19.15.

6-Chloroquinazolin-4(3*H*)-one (2b): The compound was synthesized according to the above general procedure using 2-amino-5-chlorobenzamide (2.0 g, 11.72 mmol) and formamidine acetate (2.44 g, 23.44 mmol) to afford 2b (1.87 g, 88.6%) as off white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.62 (s, 1H), 8.72 (s, 1H), 8.32 (s, 1H), 8.10–8.02 (d, J = 8Hz, 1H), 7.88–7.86 (d, J = 8Hz, 1H). ^{13}C NMR (100 MHz, DMSO-d_6): δ163.9, 153.1, 148.5, 140.1, 132.8, 129.5, 123.1, 119.7. MS (ESI) *m/z* 181 $[M+H]^+$. Anal calcd for $C_8H_5ClN_2O$: C, 53.21; H, 2.79; N, 15.51 Found C, 53.34; H, 2.80; Cl, N, 15.53.

6-Bromoquinazolin-4(3*H*)-one (2c): The compound was synthesized according to the above general procedure using 2-amino-5-bromobenzamide (2.0 g, 15.92 mmol) and formamidine acetate (2.44 g, 23.44 mmol) to afford 2c (1.89 g, 91.2%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.73 (s, 1H), 8.60 (s, 1H), 8.35 (s, 1H), 8.22–8.20 (d, J = 8Hz, 1H), 7.89–7.87 (d, J = 8Hz, 1H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 166.9, 151.5, 147.7, 132.9, 130.7, 127.1, 124.8, 121.6. MS (ESI) *m/z* 226 $[M+H]^+$. Anal calcd for $C_8H_5BrN_2O$: C, 42.70; H, 2.24; N, 12.45 Found C, 42.79; H, 2. 23; N, 12.47.

2-Methyl-4H-benzo[*d*][1,3]oxazin-4-one (4a): The compound was synthesized according to the general procedure using anthranilic acid (2.0 g, 14.58 mmol) to afford 4a (1.84 g, 78.4%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 8.19–8.17 (d, J = 8Hz, 1H), 7.94–7.91 (t, J = 12Hz, 1H), 7.77–7.75 (d, J = 8Hz, 1H), 7.58–7.55 (t, J = 12Hz, 1H), 2.63 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 166.2, 161.7, 148.3, 137.1, 130.9, 129.3, 126.7, 117.8, 27.9. MS (ESI) *m/z* 162 $[M+H]^+$. Anal calcd for $C_9H_7NO_2$: C, 67.07; H, 4.38; N, 8.69 Found C, 67.18; H, 4.37; N, 8.68.

6-Chloro-2-methyl-4H-benzo[*d*][1,3]oxazin-4-one (4b): The compound was synthesized according to the general procedure using 2-amino-5-chlorobenzoic acid (2.0 g, 11.65 mmol) to afford 4b (1.74 g, 76.7%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 8.38 (s, 1H), 8.21–8.19 (d, J = 8Hz, 1H), 7.98–7.96 (d, J = 8Hz, 1H), 2.63 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 161.2 (2C), 144.7, 137.3, 1131.9 (2C), 129.9, 115.1, 27.3. MS (ESI) *m/z* 196 $[M+H]^+$. Anal calcd for $C_9H_6ClNO_2$: C, 55.26; H, 3.09; N, 7.16 Found C, 55.82; H, 3.73; N, 7.01.

2-Methylquinazolin-4(3*H*)-one (5a): The compound was synthesized according to the general procedure using 2-methyl-4*H*-benzo[*d*][1,3]oxazin-4-one (4a) (1.6 g, 9.98 mmol) to afford 5a (1.31 g, 82.8%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.49 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.08– 8.05 (t, J = 12Hz, 1H), 7.75–7.73 (d, J = 8Hz, 1H), 7.62–7.59 (t, J = 12Hz, 1H), 2.58 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 163.7, 156.1, 147.3, 136.4, 128.5 (2C), 121.9, 23.7. MS (ESI) *m/z* 161 $[M+H]^+$. Anal calcd for $C_9H_8N_2O$: C, 67.49; H, 5.03; N, 17.49 Found C, 67.54; H, 5.02; N, 17.51.

6-Chloro-2-methylquinazolin-4(3*H*)-one (5b): The compound was synthesized according to the general procedure using 6-chloro-2-methyl-4*H*-benzo[*d*][1,3]oxazin-4-one (4b) (1.6 g, 8.22 mmol) to afford 5b (1.31 g, 82.7%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.37 (s, 1H), 8.42 (s, 1H), 8.25–8.23 (d, J = 8Hz, 1H), 7.93–7.91 (d, J = 8Hz, 1H), 2.49 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 164.2, 153.9, 149.1, 133.7 (2C), 128.9 (2C), 120.7, 23.2. MS (ESI) *m/z* 195 $[M+H]^+$. Anal calcd for $C_9H_7ClN_2O$: C, 55.54; H, 3.63; N, 14.39 Found C, 55.59; H, 3.64; N, 14.37.

2-Chloro-N-(2,6-dimethylphenyl) acetamide (6a): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 2,6-dimethylphenyl amine (1.0 g, 7.2 mmol) to afford 6a (1.08 g, 68.7%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 2.23 (s, 6H), 4.23 (s, 2H), 9.89 (s, 1H), 7.09-6.99 (m, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.2, 142.7, 131.9 (2C), 129.3 (2C), 127.1, 45.3, 18.3 (2C). MS (ESI) *m/z* 198 $[M+H]^+$. Anal calcd for $C_{10}H_{12}NO$: C, 60.76; H, 6.12; N, 7.09 Found C, 60.69; H, 6.11; N, 7.10.

2-Chloro-N-(3-chloro-2-methylphenyl)acetamide (6b): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 3-chloro-2-methylphenyl amine (1.2g, 6.9 mmol) to afford 6b (1.2 g, 71.2%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.95 (s, 1H), 4.42 (s, 2H), 2.31 (s, 3H), 7.15-7.09 (m, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.3, 140.1, 136.2 (2C), 129.5, 125.7, 115.1, 45.4, 16.3. MS (ESI) *m/z* 219 $[M+H]^+$. Anal calcd for $C_9H_9Cl_2NO$: C, 49.57; H, 4.16; N, 6.42 Found C, 49.51; H, 4.15; N, 6.41.

N-(2-Bromophenyl)-2-chloroacetamide (6c): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 2-bromophenyl amine (1.2g, 7.4 mmol) to afford **6c** (1.15 g, 70.2%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.98 (s, 1H), 4.38 (s, 2H), 8.29–8.27 (d, J = 8Hz, 1H), 8.15–8.13 (d, J = 8Hz, 1H), 7.79–7.76 (t, J = 12Hz, 1H), 7.58–7.55 (t, J = 12Hz, 1H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.5, 140.5, 132.7 (2C), 129.1, 127.3, 119.7, 43.5. MS (ESI) *m/z* 249 $[M+H]^+$. Anal calcd for $C_8H_7BrClNO$: C, 38.67; H, 2.84; N, 5.64 Found C, 38.64; H, 2.84; N, 5.65.

2-Chloro-N-(2,6-diethylphenyl)acetamide (6d): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 2,6-diethylphenyl amine (1.2g, 7.8 mmol) to afford 6d (1.3 g, 71.4%) as white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.72 (s, 21H), 7.75–7.69 (m, 3H), 4.49 (s, 2H), 2.92–2.85 (m, 4H), 1.72–1.65 (m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.3, 135.8, 131.2 (2C), 125.3, 123.2, 43.9, 25.6 (2C), 14.8 (2C). MS (ESI) *m/z* 226 $[M+H]^+$. Anal calcd for $C_{12}H_{16}ClNO$: C, 63.85; H, 7.14; N, 6.21 Found C, 63.87; H, 7.13; N, 6.20.

2-Chloro-N-(2-methyl-4-nitrophenyl)acetamide (6e): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 2-methyl-4-nitrophenyl amine (1.1g, 8.2 mmol) to afford 6e (1.4g, 75.4%) as pale yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.82 (s, 1H), 8.53 (s, 1H), 8.12–8.10 (d, J = 8Hz, 1H), 7.96–7.94 (d, J = 8Hz, 1H), 4.52 (s, 2H), 2.34 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.8, 145.7, 142.1, 139.4, 127.4, 123.5, 110.9, 43.1, 17.7. MS (ESI) *m/z* 229 $[M+H]^+$. Anal calcd for $C_9H_9ClN_2O_3$: C, 63.85; H, 7.14; N, 6.21 Found C, 63.79; H, 7.15; N, 6.22.

2-Chloro-N-(4-chlorophenyl)acetamide (6f): The compound was synthesized according to the general procedure using chloroacetyl chloride (1.55 g, 13.77 mmol) and 4-chlorophenyl amine (1.3g, 7.8 mmol) to afford 6f (1.3g, 74.2%) as off white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.81 (s, 1H), 7.89–7.75 (m, 4H), 4.51 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.1, 137.4, 134.2, 130.4 (2C), 121.7 (2C), 44.3. MS (ESI) *m/z* 205 $[M+H]^+$. Anal calcd for $C_8H_7Cl_2NO$: C, 47.09; H, 3.46; N, 6.86 Found C, 47.14; H, 3.45; N, 6.84.

2-(6-Chloro-4-oxoquinazolin-3(4*H*)-yl)-N-(2,6-dimethylphenyl)acetamide (7): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6a) (0.16 g, 0.75 mmol) and 6-Chloroquinazolin-4 (3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 7 (0.15 g, 71.9%) as white solid. M.p: 239°C–241°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.82 (s, 1H), 8.56 (s, 1H), 8.42 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.07–8.05 (d, J = 8Hz, 1H), 7.07–6.98 (m, 3H), 4.97 (s, 2H), 2.21 (s, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.2, 160.5, 150.1, 147.5, 138.3, 135.2 (2C),

131.2 (2C), 129.1 (4C), 126.4, 120.8, 52.5, 19.6 (2C). MS (ESI) *m/z* 343 $[M+H]^+$. Anal calcd for $C_{18}H_{16}ClN_3O_2$: C, 63.25; H, 4.72; N, 12.29; Found C, 63.22; H, 4.73; N, 12.27.

N-(3-Chloro-2-methylphenyl)-2-(6-chloro-4-oxoquinazolin-3(4*H*)-yl)acetamide (8): The compound was synthesized according to the general procedure using 2-chloro-N-(3-chloro-2-methylphenyl) acetamide (6b) (0.18 g, 0.71 mmol) and 6-Chloroquinazolin-4(3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 8 (0.15 g, 72.8%) as white solid. M.p: 212°C–214°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.93 (s, 1H), 8.59 (s, 1H), 8.38 (s, 1H), 8.22–8.20 (d, J = 8Hz, 1H), 8.03–8.01 (d, J = 8Hz, 1H), 7.10–7.05 (m, 3H), 4.99 (s, 2H), 2.25 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.5, 160.3, 149.4, 146.4, 140.1, 137.3 (2C), 134.4 (2C), 129.7 (3C), 124.9, 121.8, 112.5, 46.2, 14.3. MS (ESI) *m/z* 363 $[M+H]^+$. Anal calcd for $C_{17}H_{13}Cl_2N_3O_2$: C, 56.37; H, 3.62; N, 11.60 Found C, 56.41; H, 3.61; N, 11.58.

N-(2-Bromophenyl)-2-(6-chloro-4-oxoquinazolin-3(4*H*)-yl)acetamide (9): The compound was synthesized according to the general procedure using 2-chloro-N-(2-bromophenyl) acetamide (**6c**) (0.18 g, 0.77 mmol) and 6-Chloroquinazolin-4 (3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 9 (0.12 g, 70.9%) as white solid. M.p: 260°C–262°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.97 (s, 1H), 8.56 (s, 1H), 8.40 (s, 1H), 8.26-8.24 (d, J = 8Hz, 1H), 8.21-8.19 (d, J = 8Hz, 1H), 8.12–8.10 (d, J = 8Hz, 1H), 7.90–7.89 (t, J = 12Hz, 1H), 7.70–7.68 (d, J = 8Hz, 1H), 7.61–7.59 (t, J = 12Hz, 1H), 4.87 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.3, 160.7, 148.2 (2C), 135.2, 131.5 (2C), 129.5 (2C), 126.9 (3C), 126.2, 123.5, 119.5, 49.2. MS (ESI) *m/z* 393 $[M+H]^+$. Anal calcd for $C_{16}H_{11}BrClN_3O_2$: C, 48.94; H, 2.82; N, 10.70 Found C, 48.99; H, 2.82; N, 10.72.

2-(6-Chloro-4-oxoquinazolin-3(4*H*)-yl)-N-(2,6-diethylphenyl)acetamide (10): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-diethylphenyl) acetamide (6d) (0.16 g, 0.72 mmol) and 6-Chloroquinazolin-4 (3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 10 (0.15 g, 73.5%) as off-white solid. M.p: 250°C–252°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.01 (s, 1H), 8.61 (s, 1H), 8.19–8.17 (d, J = 8Hz, 1H), 8.07 (s, 1H), 7.97–9.75 (d, J = 8Hz, 1H), 7.72–7.65 (m, 3H), 4.52 (s, 2H), 2.89–2.82 (m, 4H), 1.5–1.42 (m, 4H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.1, 160.7, 147.3, 146.1, 135.2 (2C), 132.5, 130.3 (2C), 127.1 (2C), 123.5, 122.3 (3C), 52.7, 24.7 (2C), 15.7 (2C). MS (ESI) *m/z* 370 $[M+H]^+$. Anal calcd for $C_{20}H_{20}ClN_3O_2$: C, 64.95; H, 5.45; N, 11.36 Found C, 64.91; H, 5.44; N, 11.35.

2-(6-Chloro-4-oxoquinazolin-3(4*H*)-yl)-N-(2-methyl-4-nitrophenyl)acetamide (11): The compound was synthesized according to the general procedure using 2-chloro-N-(2-methyl-4-nitrophenyl) acetamide (6e) (0.15 g, 0.78 mmol) and 6-Chloroquinazolin-4 (3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 11 (0.17 g, 70.4%) as pale yellow solid. M.p: 282°C–284°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.03 (s, 1H), 8.53 (s, 1H), 8.34 (s, 1H), 8.33–8.31 (d, J = 8Hz, 1H), 8.24 (s, 1H), 8.10–8.08 (d, J = 8Hz, 1H), 8.03–8.01 (d, J = 8Hz, 1H), 7.77–7.75 (d, J = 8Hz, 1H), 4.52 (s, 2H), 2.32 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.4, 162.3, 148.9, 146.5, 144.7, 143.8, 141.6, 133.9 (2C), 129.5 (2C), 125.5, 121.5 (2), 110.2, 52.3, 18.9. MS (ESI) *m/z* 373$[M+H]^+$. Anal calcd for $C_{17}H_{13}ClN_4O_4$: C, 54.78; H, 3.52; N, 15.03 Found C, 54.81; H, 3.51; N, 15.04.

2-(6-Chloro-4-oxoquinazolin-3(4*H*)-yl)-N-(4-chlorophenyl)acetamide (12): The compound was synthesized according to the general procedure using 2-chloro-N-(4-chlorophenyl) acetamide (6f) (0.16 g, 0.76 mmol) and 6-Chloroquinazolin-4 (3*H*)-one (2b) (0.1 g, 0.68 mmol) to afford 12 (0.18 g, 72.5%) as off-white solid. M.p: 221°C–223°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.95 (s, 1H), 8.58 (s, 1H), 8.29 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.06–8.04 (d, J = 8Hz, 1H), 7.73–7.68 (m, 4H), 4.48 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.7, 162.3, 149.2, 147.4, 137.2, 134.3 (2C), 129.3 (2C), 126.9 (2C), 123.5, 120.6 (2C), 52.3. MS (ESI) *m/z* 349$[M+H]^+$. Anal calcd for $C_{16}H_{11}Cl_2N_3O_2$: C, 55.19; H, 3.18; N, 12.07 Found C, 55.69; H, 3.90; N, 12.18.

2-(6-Chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(2,6-dimethylphenyl)acetamide (13): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6a) (0.13 g, 0.76 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 13 (0.17 g, 75.1%) as white solid. M.p: 253°C–255°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.69 (s, 1H), 8.41 (s, 1H), 8.25–8.23 (d, J = 8, 1H), 8.02–8.00 (d, J = 8Hz, 1H), 7.12 (m, 3H), 4.62 (s, 2H), 2.63 (s, 3H), 2.09 (s, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.3, 162.8, 155.5, 147.4, 138.3, 133.7 (2C), 131.2 (2C), 126.5 (4C), 125.1, 120.3, 52.4, 22.3, 17.9. MS (ESI) *m/z* 356$[M+H]^+$. Anal calcd for $C_{19}H_{18}ClN_3O_2$: C, 64.91; H, 5.10; N, 11.81 Found C, 64.97; H, 5.11; N, 11.83.

2-(6-Chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(3-chloro-2-methylphenyl)acetamide (14): The compound was synthesized according to the general procedure using 2-chloro-N-(3-chloro-2-methylphenyl) acetamide (6b) (0.12 g, 0.79 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 14 (0.18 g, 78.2%) as white solid. M.p: 168°C–170°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.89 (s, 1H), 8.61 (s, 1H), 8.32–8.30 (d, J = 8Hz, 1H), 8.08–8.06 (d, J = 8Hz, 1H), 7.81–7.77 (m, 3H), 4.56 (s, 2H), 2.62 (s, 3H), 2.25 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.7, 162.3, 155.9, 147.2, 138.6, 135.3, 134.7 (2C), 132.3, 125.8 (3C), 124.7, 123.1, 112.9, 52.3, 20.1, 15.3. MS (ESI) *m/z* 377$[M+H]^+$. Anal calcd for $C_{18}H_{15}Cl_2N_3O_2$: C, 57.46; H, 4.02; N, 11.17 Found C, 57.38; H, 4.03; N, 11.15.

N-(2-Bromophenyl)-2-(6-chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (15): The compound was synthesized according to the general procedure using 2-chloro-N-(2-bromophenyl) acetamide (6c) (0.12 g, 0.73 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 15 (0.13 g, 70.8%) as white solid. M.p: 189°C–191°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.11 (s, 1H), 8.61 (s, 1H), 8.29–8.27 (d, J = 8Hz, 1H), 7.63–7.58 (m, 4H), 4.58 (s, 2H), 2.56 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 167.9, 161.2, 156.7, 146.3, 139.8, 133.6 (2C), 131.7 (2C), 126.9 (3C), 125.1, 121.3, 119.2, 53.2, 23.5. MS (ESI) *m/z* 407[M+H]$^+$. Anal calcd for $C_{17}H_{13}BrClN_3O_2$: C, 50.21; H, 3.22; N, 10.33 Found C, 50.17; H, 3.21; N, 10.31.

2-(6-Chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(2,6-diethylphenyl)acetamide (16): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-diethylphenyl) acetamide (6d) (0.13 g, 0.75 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 16 (0.13 g, 73.8%) as white solid. M.p: 201°C–203°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.07 (s, 1H), 8.57 (s, 1H), 8.25–8.23 (d, J = 8Hz, 1H), 8.06–8.04 (d, J = 8Hz, 1H), 7.79–7.72 (m, 3H), 4.57 (s, 2H), 2.64 (m, 6H), 2.53 (s, 3H), 1.32 (m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.2, 162.9, 155.5, 141.7, 135.6, 133.7 (2C), 130.2 (2C), 125.6 (2C), 123.5, 121.8 (2C), 53.8, 25.2 (2C), 21.7 17.3 (2C). MS (ESI) *m/z* 384[M+H]$^+$. Anal calcd for $C_{21}H_{22}ClN_3O_2$: C, 65.71; H, 5.78; N, 10.95 Found C, 65.66; H, 5.77; N, 10.97.

2-(6-Chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(2-methyl-4-nitrophenyl)acetamide (17): The compound was synthesized according to the general procedure using 2-chloro-N-(2-methyl-4-nitrophenyl) acetamide (6e) (0.14 g, 0.82 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 17 (0.13 g, 71.9%) as yellow solid. M.p: 245°C–247°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.07 (s, 1H), 8.62 (s, 1H), 8.32 (s, 1H), 8.10–7.96 (m, 4H), 4.71(s, 2H), 2.61 (s, 3H), 2.09 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.9, 160.3, 155.6, 146.2, 142.7, 141.5, 136.7, 132.4 (2C), 125.9 (2C), 124.3, 121.5 (2C), 108.5, 47.2, 23.3, 16.5. MS (ESI) *m/z* 387[M+H]$^+$. Anal calcd for $C_{18}H_{15}ClN_4O_4$: C, 55.89; H, 3.91; N, 14.49 Found C, 55.77; H, 3.90; N, 14.47.

2-(6-Chloro-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(4-chlorophenyl)acetamide (18): The compound was synthesized according to the general procedure using 2-chloro-N-(4-chlorophenyl) acetamide (6f) (0.14 g, 0.78 mmol) and 6-chloro-2-methylquinazolin-4 (3*H*)-one (5b) (0.14 g, 0.70 mmol) to afford 18 (0.13 g, 70.5%) as white solid. M.p: 193°C–195°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.82 (s, 1H), 8.58 (s, 1H), 8.25–8.23 (d, J = 8Hz, 1H), 8.10–8.08 (d, J = 8Hz, 1H), 7.75–7.68 (m, 4H), 4.52 (s, 2H), 2.64 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.3, 160.9, 155.5, 146.2, 137.3, 133.8 (3C), 129.7 (2C), 127.2 (2C), 122.3, 119.3 (2C), 53.5, 24.3. MS (ESI) *m/z* 363[M+H]$^+$. Anal calcd for $C_{17}H_{13}Cl_2N_3O_2$: C, 56.37; H, 3.62; N, 11.60 Found C, 56.27; H, 3.61; N, 11.62.

N-(2,6-Dimethylphenyl)-2-(4-oxoquinazolin-3(4*H*)-yl)acetamide (19): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6a) (0.13 g, 0.75 mmol) and quinazolin-4 (3*H*)-one (2a) (0.15 g, 0.67 mmol) to afford 19 (0.14 g, 74.8%) as off-white solid. M.p: 212°C–214°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.01 (s, 1H), 8.63 (s, 1H), 8.21–8.19 (d, J = 8Hz, 1H), 7.89–7.86 (t, J = 12Hz, 1H), 7.71–7.69 (d, J = 8Hz, 1H), 7.58–7.55 (t, J = 12Hz, 1H), 7.009–6.95 (m, 3H), 4.51 (s, 2H), 2.13 (s, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.1, 160.8, 149.5 (2C), 138.6, 133.9, 131.3 (2C), 128.4 (2C), 126.7 (4C), 121.3, 53.1, 18.5 (2C). MS (ESI) *m/z* 308[M+H]$^+$. Anal calcd for $C_{18}H_{17}N_3O_2$: C, 70.34; H, 5.58; N, 13.67 Found C, 70.15; H, 5.59; N, 13.69.

N-(2-Bromophenyl)-2-(4-oxoquinazolin-3(4*H*)-yl)acetamide (20): The compound was synthesized according to the general procedure using 2-chloro-N-(2-bromophenyl) acetamide (6c) (0.14 g, 0.73 mmol) and quinazolin-4 (3*H*)-one (2a) (0.15 g, 0.67 mmol) to afford 20 (0.13 g, 73.6%) as grey solid. M.p: 194°C–196°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.98 9s, 1H), 8.61 (s, 1H), 8.23–8.09 (m, 8H), 4.51 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.5, 159.9, 148.8 (2C), 140.1, 133.7, 130.7, 127.3, 126.9, 125.3 (2C), 124.8, 1221.7, 119.3, 51.8. MS (ESI) *m/z* 359[M+H]$^+$. Anal calcd for $C_{16}H_{12}BrN_3O_2$: C, 53.65; H, 3.38; N, 11.73 Found C, 53.71; H, 3.39; N, 11.71.

N-(2,6-Diethylphenyl)-2-(4-oxoquinazolin-3(4*H*)-yl)acetamide (21): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-diethylphenyl) acetamide (6d) (0.14 g, 0.75 mmol) and quinazolin-4 (3*H*)-one (2a) (0.15 g, 0.67 mmol) to afford 21 (0.13 g, 72.8%) as white solid. M.p: 256°C–258°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.83 (s, 1H), 8.62 (s, 1H), 8.21–8.19 (d, J = 8Hz, 1H), 7.95–7.92 (t, J = 12Hz, 1H), 7.73–7.71 (d, J = 8Hz, 1H), 7.65–7.62 (t, J = 12Hz, 1H), 7.20–7.12 (m, 3H), 4.58 (s, 2H), 2.64 (m, 4H), 1.34(m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.2, 160.8, 149.5 (2C), 135.2 (2C), 131.2 (2C), 128.1 (2C), 125.5, 121.5, 48.7, 21.6 (2C), 15.3 (2C). MS (ESI) *m/z* 334[M+H]$^+$. Anal calcd for $C_{20}H_{21}N_3O_2$: C, 71.62; H, 6.31; N, 12.53 Found C, 71.69; H, 6.32; N, 12.54.

N-(2-Methyl-4-nitrophenyl)-2-(4-oxoquinazolin-3(4*H*)-yl)acetamide (22): The compound was synthesized according to the general procedure using 2-chloro-N-(2-methyl-4-nitrophenyl) acetamide (6e) (0.15 g, 0.76 mmol) and quinazolin-4 (3*H*)-one (2a) (0.15 g, 0.67 mmol) to afford 22 (0.10 g, 69.8%) as yellow solid. M.p: 243°C–245°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.87 (s, 1H), 8.59 (s, 1H), 8.17–8.15 (d, J = 8Hz, 1H), 8.10–8.08 (d, J = 8Hz, 1H), 7.93–7.87 (m, 4H), 4.51 (s, 2H), 2.17 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 171.0, 162.1, 149.4 (2C), 145.2, 141.9, 137.3, 132.8, 137.5,

125.9 (3C), 121.3 (2C), 110.5, 51.7, 18.5. MS (ESI) *m/z* 339[M+H]$^+$. Anal calcd for $C_{17}H_{14}N_4O_4$: C, 60.35; H, 4.17; N, 16.56 Found C, 60.43; H, 4.16; N, 16.57.

N-(4-Chlorophenyl)-2-(4-oxoquinazolin-3(4*H*)-yl)acetamide (23): The compound was synthesized according to the general procedure using 2-chloro-N-(4-chlorophenyl) acetamide (6f) (0.16 g, 0.72 mmol) and quinazolin-4 (3*H*)-one (2a) (0.15 g, 0.67 mmol) to afford 23 (0.14g, 75.9%) as white solid. M.p: 236°C–238°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.93 (s, 1H), 8.62 (s, 1H), 8.03–7.89 (m, 8H), 4.54 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.3, 159.9, 148.3 (2C), 138.1, 133,5 (2C), 129.4 (2C), 126.9 (3C), 121.5, 120.5 (2C), 48.9. MS (ESI) *m/z* 314[M+H]$^+$. Anal calcd for $C_{16}H_{12}ClN_3O_2$: C, 61.25; H, 3.86; N, 13.39 Found C, 61.16; H, 3.87; N, 13.41.

N-(2,6-Dimethylphenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (24): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6a) (0.16 g, 0.73 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 24 (0.18g, 80.3%) as white solid. M.p: 210°C–212°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.72 (s, 1H), 8.13–8.11 (d, J = 8Hz, 1H), 7.82–7.79 (t, J = 12Hz, 1H), 7.63–7.61 (d, J = 8Hz, 1H), 7.52–7.49 (t, J = 12Hz, 1H), 7.08 (m, 3H), 5.02 (s, 2H), 2.59 (s, 3H), 2.22 (s, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.5, 162.3, 157.3, 147.3, 138.3, 134.2, 130.9 (2C), 129.1 (3C), 128.3 (3C), 119.3, 47.3, 23.4, 18.5 (2C). MS (ESI) *m/z* 322[M+H]$^+$. Anal calcd for $C_{19}H_{19}N_3O_2$: C, 71.01; H, 5.96; N, 13.08 Found C, 71.11; H, 5.97; N, 13.10.

N-(3-Chloro-2-methylphenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (25): The compound was synthesized according to the general procedure using 2-chloro-N-(3-chloro-2-methylphenyl) acetamide (6b) (0.15 g, 0.71 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 25 (0.17g, 78.2%) as white solid. M.p: 198°C–200°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.02 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.15–8.12 (d, J = 8Hz, 1H), 7.82–7.80 (d, J = 8Hz, 1H), 7.68–7.65 (t, J = 12Hz, 1H), 7.27–7.20 (m, 3H), 4.59 (s, 2H), 2.62 (s, 3H), 2.19(s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.7, 161.5, 155.7, 147.3, 139.2, 135.1, 133.9 (2C), 128.9 (2C), 126.1 (2C), 125.7, 121.7, 112.1, 51.3, 23.5, 14.3. MS (ESI) *m/z* 343[M+H]$^+$. Anal calcd for $C_{18}H_{16}ClN_3O_2$: C, 63.25; H, 4.72. N, 12.29 Found C, 63.33; H, 4.71; N, 12.27.

N-(2-Bromophenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (26): The compound was synthesized according to the general procedure using 2-chloro-N-(2-bromophenyl) acetamide (6b) (0.16 g, 0.75 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 26 (0.17g, 77.9%) as white solid. M.p: 242°C–244°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.04 (s, 1H), 8.23–8.11 (m, 8H), 4.59 (s, 2H), 2.65 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.7, 161.8, 154.8, 147.1, 140.1, 133.9, 132.5 (2C), 129.3 (2C), 126.6 (2C), 121.4, 119.6, 48.3, 24.4. MS (ESI) *m/z* 372[M+H]$^+$. Anal calcd for $C_{17}H_{14}BrN_3O_2$: C, 54.86; H, 3.79; N, 11.29 Found C, 54.94; H, 3.80; N, 11.27.

N-(2,6-Diethylphenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (27): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-diethylphenyl) acetamide (6c) (0.14 g, 0.7 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 27 (0.14 g, 73.7%) as white solid. M.p: 235°C–237°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.95 (s, 1H), 8.28–8.26 (d, J = 8Hz, 1H), 8.18–8.15 (t, J = 12Hz, 1H), 7.77–7.75 (d, J = 8Hz, 1H), 7.64–7.61 (t, J = 12Hz, 1H), 7.34–7.28 (m, 3H), 4.51 (s, 2H), 2.64 (s, 3H), 2.52 (m, 4H), 1.34 (m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.2, 161.3, 154.9, 147.4, 135.5, 133.9, 131.4 (2C), 128.5 (2C), 125.6, 122.9 (2C), 121.7, 48.3, 24.2 (2C), 23.7, 15.5. MS (ESI) *m/z* 350[M+H]$^+$. Anal calcd for $C_{21}H_{23}N_3O_2$: C, 72.18; H, 6.63; N, 12.03 Found C, 72.09; H, 6.64; N, 12.02.

N-(2-Methyl-4-nitrophenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (28): The compound was synthesized according to the general procedure using 2-chloro-N-(2-methyl-4-nitrophenyl) acetamide (6d) (0.15 g, 0.73 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 28 (0.15 g, 76.2%) as yellow solid. M.p: 270°C–272°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.03 (s, 1H), 8.64 (s, 1H), 8.23–8.21 (d, J = 8Hz, 1H), 8.07–8.05 (d, J = 8Hz, 1H), 7.89–7.80 (m, 4H), 4.60 (s, 2H), 2.64 (s, 3H), 2.18 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.3, 160.9, 154.2, 147.5, 145.6, 143.1, 135.6, 132.8, 127.3 (3C), 126.1, 122.4 (2C), 109.4, 47.3, 22.9, 18.1. MS (ESI) *m/z* 353[M+H]$^+$. Anal calcd for $C_{18}H_{16}N_4O_4$: C, 61.36; H, 4.58; N, 15.90 Found C, 61.27; H, 4.59; N, 15.88.

N-(4-Chlorophenyl)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)acetamide (29): The compound was synthesized according to the general procedure using 2-chloro-N-(4-chlorophenyl) acetamide (6e) (0.12 g, 0.71 mmol) and 2-methylquinazolin-4 (3*H*)-one (5a) (0.16 g, 0.77 mmol) to afford 29 (0.18 g, 78.6%) as white solid. M.p: 237°C–239°C.^{1}H NMR (400 MHz, DMSO-d_6): δ 9.81 (s, 1H), 8.11–7.98 (m, 8H), 4.58 (s, 2H), 2.60 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.3, 161.5, 154.9, 148.1, 138.3, 133.4 (2C), 130.2 (2C), 17.5 (3C), 121.3, 120.1 (2C), 52.3, 23.4. MS (ESI) *m/z* 328[M+H]$^+$. Anal calcd for $C_{17}H_{14}ClN_3O_2$: C, 62.30; H, 4.31; N, 12.82 Found C, 62.39; H, 4.30; N, 12.80.

2-(6-Bromo-4-oxoquinazolin-3 (4*H*)-yl)-N-(2,6-dimethylphenyl)acetamide (30): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6a) (0.13 g, 0.74 mmol) and 6-Bromoquinazolin-4 (3*H*)-one (2c) (0.17 g, 0.79 mmol) to afford 30 (0.19 g, 79.5%) as white solid. M.p: 241°C–243°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.97 (s, 1H), 8.61 (s, 1H), 8.42 (s, 1H), 8.12–8.10 (d, J = 8Hz, 1H), 7.99–7.97 (d, J = 8Hz, 1H),

7.53–7.48 (m, 3H), 4.57 (s, 2H), 2.21 (s, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.9, 162.3, 147.3 (2C), 138.6, 137.2, 133.4, 132.7 (2C), 129.5 (2C), 127.3, 125.2, 123.1, 121.3, 51.2, 19.3 (2C). MS (ESI) *m/z* 387[M+H]$^+$. Anal calcd for $C_{18}H_{16}BrN_3O_2$: C, 55.97; H, 4.18; N, 10.88 Found C, 55.88; H, 4.17; N, 10.90.

2-(6-Bromo-4-oxoquinazolin-3(4*H*)-yl)-N-(3-chloro-2-methylphenyl)acetamide (31): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-dimethylphenyl) acetamide (6b) (0.13 g, 0.74 mmol) and 6-bromoquinazolin-4 (3*H*)-one (2c) (0.16 g, 0.77 mmol) to afford 31 (0.13 g, 72.1%) as off-white solid. M.p: 215°C–217°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.02 (s, 1H), 8.64 (s, 1H), 8.39 (s, 1H), 8.09–8.07 (d, J = 8Hz, 1H), 7.95–7.93 (d, J = 8Hz, 1H), 7.61–7.55 (m, 3H), 4.58 (s, 2H), 2.28 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.5, 162.3, 148.7 (2C), 139.2, 136.3 (2C), 134.7 (2C), 131.9, 126.9, 124.9 (2C), 123.1, 120.8, 113.5, 54.2, 16.3. MS (ESI) *m/z* 407[M+H]$^+$. Anal calcd for $C_{17}H_{13}BrClN_3O_2$: C, 50.21; H, 3.22; N, 10.33 Found C, 50.28; H, 3.21; N, 10.35.

2-(6-Bromo-4-oxoquinazolin-3(4*H*)-yl)-N-(2-bromophenyl)acetamide (32): The compound was synthesized according to the general procedure using 2-chloro-N-(2-bromophenyl) acetamide (**6c**) (0.14 g, 0.76 mmol) and 6-bromoquinazolin-4 (3*H*)-one (2c) (0.16 g, 0.77 mmol) to afford 32 (0.16 g, 78.3%) as off-white solid. M.p: 280°C–282°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.09 (s, 1H), 8.53 (s, 1H), 8.43 (s, 1H), 8.27-8.25 (d, J = 8Hz, 1H), 8.03-8.01 (d, J = 8Hz, 1H), 7.69-7.67 (d, J = 8Hz, 1H), 7.61-7.59 (d, J = 8Hz, 1H), 7.39-7.36 (t, J = 12Hz, 1H), 7.16-7.13 (t, J = 12Hz, 1H), 4.95 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.1, 163.2, 149.2 (2C), 139.3, 137.2, 133.3, 131.9 (2C), 129.1, 126.7, 125.2 (2C), 122.9, 118.2, 49.8. MS (ESI) *m/z* 438[M+H]$^+$. Anal calcd for $C_{16}H_{11}Br_2N_3O_2$: C, 43.97; H, 2.54; N, 9.61 Found C, 43.91; H, 2.54; N, 9.62.

2-(6-Bromo-4-oxoquinazolin-3(4*H*)-yl)-N-(2,6-diethylphenyl)acetamide (33): The compound was synthesized according to the general procedure using 2-chloro-N-(2,6-diethylphenyl) acetamide (6d) (0.15 g, 0.79 mmol) and 6-bromoquinazolin-4 (3*H*)-one (2c) (0.16 g, 0.77 mmol) to afford 33 (0.15 g, 77.4%) as white solid. M.p: 271°C–273°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.97 (s, 1H), 8.58 (s, 1H), 8.31 (s, 1H), 8.13–8.11 (d, J = 8Hz, 1H), 7.88–7.86 (d, J = 8Hz, 1H), 7.53–7.48 (m, 4H), 4.50 (s, 2H), 2.54 (m, 4H), 1.36 (m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.5, 162.7, 148.9 (2C), 137.2, 135.1, 132.7, 131.2 (2C), 124.3 (2C), 123.2, 121.9 (3C), 49.7, 24.2 (2C), 16.3 (2C). MS (ESI) *m/z* 415[M+H]$^+$. Anal calcd for $C_{20}H_{20}BrN_3O_2$: C, 57.98; H, 4.87; N, 10.14 Found C, 57.86; H, 4.88; N, 10.16.

2-(6-Bromo-2-methyl-4-oxoquinazolin-3(4*H*)-yl)-N-(2-methyl-4-nitrophenyl)acetamide (34): The compound was synthesized according to the general procedure using 2-chloro-N-(2-methyl-4-nitrophenyl) acetamide (6e) (0.14 g, 0.77 mmol) and 6-bromoquinazolin-4 (3*H*)-one (2c) (0.16 g, 0.77 mmol) to afford 34 (0.14 g, 75.4%) as pale yellow solid. M.p: 189°C–191°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.85 (s, 1H), 8.60 (s, 1H), 8.34 (s, 1H), 8.09–7.99 (m, 4H), 4.51 (s, 2H), 2.71 (s, 3H), 2.17 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 169.3, 161.7, 155.2, 146.3, 144.6, 143.1, 137.4, 135.8, 133.5, 124.2, 123.1 (2C), 121.9 (2C), 109.1, 47.2, 23.1, 18.5. MS (ESI) *m/z* 432[M+H]$^+$. Anal calcd for $C_{18}H_{15}BrN_4O_4$: C, 50.13; H, 3.51; N, 12.99 Found C, 50.21; H, 3.50; N, 12.97.

2-(6-Bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(4-chlorophenyl)acetamide (35): The compound was synthesized according to the general procedure using 2-chloro-N-(4-chlorophenyl) acetamide (6f) (0.15 g, 0.79 mmol) and 6-bromoquinazolin-4 (3*H*)-one (2c) (0.16 g, 0.77 mmol) to afford 35 (0.13 g, 73.8%) as white solid. M.p: 178°C–180°C. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.02 (s, 1H), 8.61 (s, 1H), 8.32–8.30 (d, J = 8Hz, 1H), 8.07–8.05 (d, J = 8Hz, 1H), 7.63–7.58 (m, 4H), 4.58 (s, 2H), 2.54 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 170.2, 161.3, 156.1, 143.8, 137.2 (2C), 134.4, 132.8, 130.7 (2C), 125.3, 121.9, 121.5 (2C), 47.3, 23.7. MS (ESI) *m/z* 407 [M+H]$^+$. Anal calcd for $C_{17}H_{13}BrClN_3O_2$: C, 50.21; H, 3.22; N, 10.33 Found C, 50.29; H, 3.21; N, 10.35.